Registration Dossier

Administrative data

Link to relevant study record(s)

Description of key information

A toxicokinetic assessment is available which describes the % of absorption after oral, inhalation and dermal exposures to Cyanox 1790 for risk assessment purposes. The assessment is based on physico-chemical properties of Cyanox 1790 and the available experimental data.  

Key value for chemical safety assessment

Bioaccumulation potential:
high bioaccumulation potential
Absorption rate - oral (%):
10
Absorption rate - dermal (%):
10
Absorption rate - inhalation (%):
100

Additional information

Once absorbed in the gastro-intestinal tract, Cyanox 1790 might be metabolized. Excretion of Cyanox 1790 and its metabolites will occur via the bile (high molecular weight) or the urine (low molecular weight). Based on the high partition coefficient, Cyanox 1790 may accumulate in adipose tissue. For risk assessment purposes, the oral absorption is set at 10%, the inhalation absorption is set at 100% and the dermal absorption is set at 10%.